Joyce A. O'Shaughnessy, MD

Articles

Unmet Needs and Future Direction in HER2+ Breast Cancer

July 29th 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

July 29th 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

Clinical Perspectives on Managing ILD Related to T-DXd

July 22nd 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

Overview of DESTINY-Breast06

July 22nd 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

July 15th 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

July 15th 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Optimal Management Strategies in Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

July 8th 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

July 8th 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer

August 23rd 2022

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB

June 8th 2022

Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.

Patient Scenario: HER2+ Metastatic Breast Cancer

June 1st 2022

Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, consider how they would approach the treatment of a patient with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

June 1st 2022

Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.